Palatin concludes Phase II trial of combination therapy for obesity
"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
News Medical10d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
News Medical11d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs
Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Business Insider14d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread ...
Morningstar14d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...
C&EN27d
Bioinspired Nanofluidic Circuits with Integrating Excitatory and Inhibitory Synapses
Institute of Flexible Electronics (IFE, Future Technologies), Xiang’an Campus, Xiamen University, Xiang’an South Road, Xiamen 361102, Fujian, China State Key Laboratory of Physical Chemistry of Solid ...